Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1850149rdf:typepubmed:Citationlld:pubmed
pubmed-article:1850149lifeskim:mentionsumls-concept:C0699885lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C0004927lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C0016911lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C0027646lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C0178759lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C1979874lld:lifeskim
pubmed-article:1850149lifeskim:mentionsumls-concept:C0024943lld:lifeskim
pubmed-article:1850149pubmed:issue4lld:pubmed
pubmed-article:1850149pubmed:dateCreated1991-5-23lld:pubmed
pubmed-article:1850149pubmed:abstractText33 patients with tumours of the urinary bladder were studied via MR, both with and without the paramagnetic contrast medium Gd-DTPA. Results were compared with the final pathological classification after TUER and bimanual palpation. The signal intensity ratio of tumour tissue/fat and tumour/muscle were calculated on T1 weighted images and after GD-DTPA and examined for their statistical significance. The increase in signal intensity of the tumours was statistically significant (Wilcoxon test p less than 0.01). There was no advantage for the T2 weighted images compared with Gd-contrasted enhanced T1 weighted images. MRI staging was correct in 28 out of 33 cases (accuracy 84.8%). Because of the relatively short acquisition time of T1 weighted images and the specific tumour enhancement, administration of Gd-DTPA proved to be of help in the staging of the carcinoma of the bladder. Two small tumours and regressive changes in central areas of tumours were recognised after Gd-DTPA.lld:pubmed
pubmed-article:1850149pubmed:languagegerlld:pubmed
pubmed-article:1850149pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:citationSubsetIMlld:pubmed
pubmed-article:1850149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1850149pubmed:statusMEDLINElld:pubmed
pubmed-article:1850149pubmed:monthAprlld:pubmed
pubmed-article:1850149pubmed:issn1438-9029lld:pubmed
pubmed-article:1850149pubmed:authorpubmed-author:SchmollerHHlld:pubmed
pubmed-article:1850149pubmed:authorpubmed-author:JoosHHlld:pubmed
pubmed-article:1850149pubmed:authorpubmed-author:DoringerEElld:pubmed
pubmed-article:1850149pubmed:authorpubmed-author:ForstnerRRlld:pubmed
pubmed-article:1850149pubmed:issnTypePrintlld:pubmed
pubmed-article:1850149pubmed:volume154lld:pubmed
pubmed-article:1850149pubmed:ownerNLMlld:pubmed
pubmed-article:1850149pubmed:authorsCompleteYlld:pubmed
pubmed-article:1850149pubmed:pagination357-63lld:pubmed
pubmed-article:1850149pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:meshHeadingpubmed-meshheading:1850149-...lld:pubmed
pubmed-article:1850149pubmed:year1991lld:pubmed
pubmed-article:1850149pubmed:articleTitle[MRT of bladder carcinoma: tumor staging and gadolinium contrast behavior].lld:pubmed
pubmed-article:1850149pubmed:affiliationRöntgendiagnostisches Zentralinstitut der Landeskrankenanstalten, Salzburg.lld:pubmed
pubmed-article:1850149pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1850149pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1850149pubmed:publicationTypeEnglish Abstractlld:pubmed